医師の世論調査：製薬企業は及第点だが、医療情報提供においてトップクラスではない

医師は自分1人で治療を決定するわけではありません。同僚との話し合い、最新の臨床研究、製薬企業を含む信頼できる情報源に頼っています。メディカルアフェアーズチームは、医師のニーズに合った適切なコンテンツを提供することで、医師のニーズに応えようとしています。

医師がどこに答えを求めに行くのか、受け取る情報の質をどのように評価するのか、そして情報を消費する際の彼らの習慣を見極めることは、メディカルアフェアーズの専門家が医師が何を望み、必要としているのか、その核心に迫るための鍵となります。

当レポートでは、フランス、ドイツ、イタリア、スペイン、英国、米国の医師426人を対象に世論調査を行い、製薬企業が医療情報のニーズや選好にどの程度応えているかについての意見を集めました。医師は、循環器科（n=135）、内分泌科（n=53）、神経科（n=90）、腫瘍科（n=98）、リウマチ科（n=50）の5つの専門部門で活動しています。

回答された主な質問

• 1. 薬物治療や疾患に関する情報への現在のアクセスについて、全体としてどの程度満足していますか。
• 2. 医薬品や疾患に関する情報を入手する際に、製薬企業を第一選択とする頻度を、その他の情報源と比較して述べてください。
• 3. 製薬企業からの医薬品や疾病に関する情報は、どの程度信頼できると思いますか。
• 4. 製薬企業からの医薬品や疾病に関する情報は、あなたのニーズや関心にどの程度関連していますか。
• 5. 製薬企業から送られてくる医薬品や疾患の情報は、どの程度タイムリーですか。

Physicians don't make treatment decisions on their own. They rely on discussions with colleagues, the latest clinical research and trusted sources - including pharma - to inform them. Medical affairs teams seek to meet doctors' needs by delivering tailored, relevant content.

Determining where physicians go for answers, how they gauge the quality of the information they receive and their habits when it comes to consuming it is key to helping medical affairs professionals get to the heart of what doctors want and need.

To help shed light on this, FirstWord polled 426 physicians from France, Germany, Italy, Spain, the UK, and the US to gather their views on how well pharma is meeting their medical information needs and preferences. The doctors work across five specialties: cardiology (n = 135), endocrinology (n = 53), neurology (n = 90), oncology (n = 98), and rheumatology (n = 50).

Key Questions Answered:

• 1. How satisfied are you overall, with your current access to information relating to drug treatments and disease?
• 2. Please indicate how often pharmaceutical companies are your first choice for accessing drug and disease information versus other sources.
• 3. How reliable do you consider the drug and disease information that comes from pharmaceutical companies?
• 4. How relevant to your needs/interests is the drug and disease information that comes from pharmaceutical companies?
• 5. How timely is the drug and disease information that comes from pharmaceutical companies?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.